Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changes in airway cross sectional areas during residual neuromuscular blockade, and after reversal
2024-519777-19-00Phase 4Authorised
- Sponsor
- University of Debrecen
- Start
- Jan 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rocuronium and Sugammadex in neuromuscular block (NMB), sponsored by University of Debrecen. Primary endpoint: Differences in retroglossal pharyngeal cross sectional areas at different TOF values. Planned start Jan 2026; status: authorised.
02
Drugs
rocuroniumSugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2024-519777-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519777-19-00.